News & Resources
30 December 2022
OncoC4 Announces First Patient Dosed in PRESERVE-004, a Phase 2 Clinical Trial of ONC-392 in Combination with KEYTRUDA® (Pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer
The Phase 2 multicenter, open-label combination trial builds upon the promising results of monotherapeutic activity of ONC-392 seen in previous clinical trial
DEC 30, 2022, Rockville, Maryland -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced that the first patient has been dosed in the Phase 2 combination study of ONC-392, a nextgen target-preserving anti-CTLA-4 antibody and KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with platinum-resistant ovarian cancer (PROC) (PRESERVE-004, NCT05446298).
07 November 2022
OncoC4 to Present Positive Data from Ongoing Phase 1/2 PRESERVE-001 Trial of ONC-392 in Combination with pembrolizumab at SITC 2022
- 30% ORR and 90% DCR in evaluable patients were achieved in the dose escalation portion of the study in metastatic cancer patients
- Initial results from dose-expansion show 5 partial responses (PR) and 1 disease stabilization (SD) in 6 evaluable metastatic melanoma patients
Nov 07, 2022, Rockville, Maryland -- OncoC4, Inc., a clinical-stage biopharma company developing novel immunotherapies for cancer, today announced clinical and safety data from the ongoing Phase 1/2 PRESERVE-001 trial for the part involving ONC-392 in combination with pembrolizumab in metastatic cancer. ONC-392 is an anti-CTLA-4 monoclonal antibody that preserves the CTLA-4 immune tolerance checkpoint function as a single agent in advanced solid tumors or in combination with anti-PD-(L)1 therapy.
26 April 2022
Oncoc4 Announces Fast Track Designation Granted By The U.S. FDA For ONC-392 Monotherapy In PD(L)1-Resistant NSCLC
A Phase 1b clinical trial of ONC-392 in PD(L)1-resistant NSCLC is currently underway
April 25, 2022, Rockville, Maryland -- OncoC4, Inc., a clinical stage biopharma company developing novel immunotherapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ONC-392, the Company’s next-gen anti-CTLA-4 monoclonal antibody (mAb) that preserves the CTLA-4 immune checkpoint function, as a single agent for the treatment of patients with metastatic non-small cell lung carcinoma (NSCLC) who have had disease progression on prior anti-PD-(L)1 therapy.
01 April 2022
Dr. Yang Liu Acknowledged as Top 20 Dynamic CEOs of 2022
ROCKVILLE, Md., Mar. 31, 2022 - The CEO Publication, a unique digital platform featuring the industry experts who have created ripples across various areas of expertise, has acknowledged Dr. Yang Liu, Chairman, CEO & CSO, OncoC4 — a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biologicals for cancer treatment — one among the “Top 20 Dynamic CEOs of 2022″ who is transforming the industry with his unique solutions. The CEO Publication has become a pioneering magazine owing to their unique coverage of news, articles & industry leaders concentrating on transforming various arenas.
15 March 2022
OncoC4 Recognized as a Top 10 Immunotherapy Solutions Providers
ROCKVILLE, Md., Mar. 15, 2022 - OncoC4, Inc. is recognized by Pharma Tech Outlook as one of the "Top 10 Immunotherapy Solutions Providers - 2022".
18 February 2022
Dr. Pan Zheng of OncoC4 is Inducted into the 2022 College of Fellow of AIMBE
ROCKVILLE, Md., Feb. 18, 2022 - OncoC4, Inc. is elated to announce that its co-founder and Chief Medical Officer, Dr. Pan Zheng, has been selected by the American Institute for Medical and Biological Engineering (AIMBE) to its 2022 College of Fellows.
- 1
- 2